Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
Poseida Therapeutics (Nasdaq: PSTX) will participate in the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Poseida Therapeutics (Nasdaq: PSTX) will participate in the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024. The company's CEO, Kristin Yarema, Ph.D., will join a virtual fireside chat at 7:55 am PT / 10:55 am ET. A live webcast and a replay accessible for 90 days will be available on Poseida's website.
Positive
- Increased visibility through participation in Stifel's 2024 Virtual Cell Therapy Forum, potentially attracting investor interest.
Negative
- None.
Details
News Market Reaction – PSTX
The recorded move for PSTX in the trading session of this news was +0.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-participation-in-stifels-2024-virtual-cell-therapy-forum-302184670.html
SOURCE Poseida Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.